Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     

JOHNSON & JOHNSON

(JNJ)
  Report
Delayed Nyse  -  01:00 2022-11-25 pm EST
177.24 USD   +0.13%
11/23Sector Update: Health Care Stocks Advancing Wednesday Afternoon
MT
11/23Sector Update: Health Care Stocks Still Advancing in Wednesday Trading
MT
11/23Sector Update: Health Care
MT
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Tension Over Copay Assistance And Maximizer Programs Continues

10/05/2022 | 12:10pm EST

In early May, a subsidiary of Johnson & Johnson ("J&J") that operates copay assistance programs for J&J's pharmaceutical companies brought suit against Save On SP, LLC, ("SaveOnSP"), a company that operates copay maximizer programs on behalf of insurers and PBMs. J&J's complaint, which alleges one count of tortious interference and a second count of deceptive trade practices, is one of the most high-profile and closely watched legal actions that a pharmaceutical manufacturer has taken against a copay maximizer program.

The suit centers on the Janssen CarePath Program, a J&J program that provides patients enrolled in private commercial plans up to $20,000 annually in copay assistance for 44 high-priced Janssen drugs, including several complex biologic treatments for various cancers and serious immunological conditions. CarePath payments are designed to count towards the patient's out-of-pocket ("OOP") maximum, and the terms and conditions patients must assent to receive assistance prohibit patients from using the copay assistance "with any other coupon, discount, prescription savings card, free trial, or other offer."

According to J&J's complaint, SaveOnSP operated a complex arrangement to capture CarePath's assistance - meant for patients - for it and its plan clients resulting in J&J paying more than $100 million is assistance than it otherwise would have. Notably, J&Js claims are limited to state tortious interference and deceptive trade practices because there are currently no federal regulatory or state insurance laws that would prohibit such an arrangement, a fact SaveOnSP highlighted in its motion to dismiss filed in July.

The issue of whether copay assistance programs are permitted under federal law is complicated. Federal regulations currently give plans, in the absence of applicable state restrictions, discretion to exclude manufacturer assistance from a patient's cost sharing obligation. However, three patient advocacy groups filed a suit against HHS in August 2022 arguing that these federal regulations are invalid because they are inconsistent with the ACA's definition of "cost-sharing".

While many states have passed laws to require health plans to apply any manufacturer assistances towards a patients OOP maximum, for complicated reasons involving ERISA pre-emption, such laws do not apply to the types of self-funded plans such as SaveOnSP's plan clients. Thus, other manufacturers and plans are likely closely watching this case to see whether such state law theories will be able to stick.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

Mr Mintz ..
Mintz
One Financial Center
Boston
MA 02111
UNITED STATES
Tel: 6175426000
Fax: 6175422241
E-mail: www.mintz.com
URL: www.mintz.com

© Mondaq Ltd, 2022 - Tel. +44 (0)20 8544 8300 - http://www.mondaq.com, source Business Briefing

All news about JOHNSON & JOHNSON
11/23Sector Update: Health Care Stocks Advancing Wednesday Afternoon
MT
11/23Sector Update: Health Care Stocks Still Advancing in Wednesday Trading
MT
11/23Sector Update: Health Care
MT
11/23Correction: Fed Minutes Eyed for Signs of Slower Fed Rate Hikes as ETFs, Stoc..
MT
11/23Fed Minutes Eyed for Signs of Slower Fed Rate Hikes as ETFs, Stock Futures Inch Higher ..
MT
11/23Johnson & Johnson's Janssen Pharmaceutical Says Phase 3 Trial of Major Depressive Disor..
MT
11/21Insider Sell: Johnson & Johnson
MT
11/21JOHNSON & JOHNSON : Ex-dividend day for
FA
11/18Vaccines and drugs in the pipeline for RSV
RE
11/18Markets are still on a roller coaster ride
MS
More news
Analyst Recommendations on JOHNSON & JOHNSON
More recommendations
Financials (USD)
Sales 2022 95 045 M - -
Net income 2022 20 677 M - -
Net cash 2022 10 194 M - -
P/E ratio 2022 22,3x
Yield 2022 2,46%
Capitalization 463 B 463 B -
EV / Sales 2022 4,77x
EV / Sales 2023 4,54x
Nbr of Employees 141 700
Free-Float 83,8%
Chart JOHNSON & JOHNSON
Duration : Period :
Johnson & Johnson Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends JOHNSON & JOHNSON
Short TermMid-TermLong Term
TrendsBullishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 23
Last Close Price 177,24 $
Average target price 181,36 $
Spread / Average Target 2,33%
EPS Revisions
Managers and Directors
Joaquin Duato Chief Executive Officer & Director
Joseph J. Wolk Chief Financial Officer & Executive Vice President
Matthew Stuckley Senior Financial Analyst-Janssen Commercial Pharm
Alex Gorsky Executive Chairman
Peter Shen Global Head-Research & Development
Sector and Competitors
1st jan.Capi. (M$)
JOHNSON & JOHNSON3.61%463 391
ELI LILLY AND COMPANY30.95%347 052
ABBVIE INC.17.89%282 189
PFIZER, INC.-16.66%276 231
MERCK & CO., INC.40.27%272 555
ROCHE HOLDING AG-17.86%270 482